Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809560 | 0.97 | MAPT (0.51) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL9263357 | 0.89 | KMT2A (0.60) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL28440147 | 0.84 | PDE4B (0.56) | TSHRMAPTKMT2ALMNAPDE4B | |
| SCHEMBL2743413 | 0.83 | KMT2A (0.54) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3841701 | 0.83 | HDAC1 (0.58) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL9541227 | 0.83 | PDE4B (0.73) | TSHRMAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL1533298 | 0.83 | NPC1 (0.72) | TSHRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL941120 | 0.82 | TDP1 (0.62) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1531237 | 0.82 | ERCC5 (0.58) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL27833185 | 0.81 | L3MBTL1 (0.52) | MAPTMEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078337-A1 | CDK8/19 DUAL INHIBITORS AND METHODS OF USE | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-11 | — | — | WO | disclosed |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| WO-2007084319-A2 | DIARYL PIPERIDINES AS CB1 MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-6498179-B1 | SUCH AS 4-(4-CHLOROPHENYL)-5-(3-(2-METHOXYPHENOXY)PROPYL)-2-(2-METHYL-1 -IMIDAZOLYL)OXAZOLE; INSULIN SECERTION PROMOTING AND BLOOD SUGAR DEPRESSING EFFECT; DIABETES; LOW TOXICITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-0891340-B1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0721942-B1 | TETRACYCLIC COMPOUND | KYOWA HAKKO KOGYO KK (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-6177452-B1 | ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0891340-A1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036882-A1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-09 | — | — | WO | disclosed |
| US-5646283-A | IMMUNOSUPPRESSANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-07-08 | — | — | US | disclosed |
| EP-0721942-A1 | NOVEL TETRACYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-07-17 | — | — | EP | disclosed |
| US-4839360-A | ANTIDEPRESSANTS; NERVOUS AND PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS | TANABE SEIYAKU CO., LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0270093-A2 | Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties | TANABE SEIYAKU CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | TSHR 1808/4885MAPT 1218/4885MEN1 2566/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | TSHR 43/4885MAPT 4794/4885MEN1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.